Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528298 | 0.84 | MAPT (0.47) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL3527495 | 0.80 | MAPT (0.46) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL2216712 | 0.80 | KDM4E (0.42) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL3527600 | 0.78 | MAPT (0.43) | KDM4ECYP1A2CYP3A4MAPTCYP2C19 | |
| SCHEMBL2215302 | 0.76 | KDM4E (0.41) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL3533615 | 0.73 | TRPM8 (0.36) | ALDH1A1KDM4EMAPTFFAR1POLB | |
| SCHEMBL28967097 | 0.72 | SMN1; SMN2 (0.56) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL3527628 | 0.70 | KDM4E (0.44) | ALDH1A1KDM4EFFAR1PTGDR2KMO | |
| SCHEMBL30076472 | 0.69 | FFAR1 (0.52) | MAPTFFAR1 | |
| SCHEMBL4878167 | 0.68 | MAPT (0.53) | ALDH1A1CYP1A2CYP3A4MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575210-B2 | Use of indole derivatives as NURR-1 activators for treating parkinson's disease | LABORATOIRES FOURNIER SA (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20110178150-A1 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease | LABORATORIES FOURNIER S.A. (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178150-A1 | Use of Indole Derivatives as NURR-1 Activators for Treating Parkinson's Disease | NCOR1, NR0B1, NCOR2 | ALDH1A1 1383/4885KDM4E 1496/4885CYP1A2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.